

IN THE CLAIMS


Please withdraw Claims 4, 8, 9,

Please cancel Claims 15, 17, 20, 22, 24, 25, 28, 33-42, 47 and 49 without prejudice to minimize patenting expenses.

Please amend Claim 2, 5, 6, 10, 11, 12, 13, 14, 16, 18, 19, 21, 23, 26, 27, 29, 31, 32, 43- 46, 48.

Amendments to the Claims

1. (Original). A compound having a formula I,



I

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

A₂ and A₃ are independently: CH₂, O or S;

E₁, E₂, E₃, E₄ and E₅ are each CH or substituted carbon bearing A₂ and R³; or at least one of E₁, E₂, E₃, E₄ and E₅ is nitrogen and each of others being CH or substituted carbon bearing A₂ and R³;

Q is: -C(O)OR⁶, or R^{6A};

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

Z is: a) aryl;
b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
- d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R^7 ;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1 - C_6 alkyl,

$(CH_2)_n C_3$ - C_8 cycloalkyl, or

R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and

wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R^3 is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C_1 - C_6 alkyl,


C_1 - C_6 alkoxy, or

C_3 - C_8 cycloalkyl;

R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl;

R^6 is: hydrogen, C_1 - C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



R⁷ is: hydrogen,
 oxo,
 nitro,
 cyano,
 hydroxyl,
 halo,
 haloalkyl,
 haloalkyloxy,
 aryloxy,
 arylalkyl,
 aminoalkyl,
 C₁-C₆ alkyl,
 C₁-C₆ alkoxy,
 (CH₂)_nC₃-C₈ cycloalkyl,
 C(O)R⁹,
 C(O)OR⁹,
 C(=NOR⁸)R⁹,
 CR⁸(OH)R⁹,
 C[=C(R⁸)₂]R⁹,
 OR⁹,
 SR⁹ or
 S(O)_pR⁹;

R⁸ is: hydrogen or C₁-C₆ alkyl; and

R⁹ is: hydrogen,

C₁-C₆ alkyl,

C₃-C₈ cycloalkyl,

aryl,


heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl, C₁-C₆ alkoxy and C₃-C₈ cycloalkyl.

2. (Currently Amended). The compound of Claim 1, wherein the compound ~~having a~~ is represented by a compound of formula II,



II

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

A₂ is: O or S or CH₂;

Q is: -C(O)OR⁶, or R^{6A};

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

Z is: a) aryl;

b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
- d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R^7 ;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1 - C_6 alkyl,

$(CH_2)_n C_3$ - C_8 cycloalkyl, or

R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and

wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R^3 is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C_1 - C_6 alkyl,


C_1 - C_6 alkoxy, or

C_3 - C_8 cycloalkyl;

R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl;

R^6 is: hydrogen, C_1 - C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



R⁷ is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkoxy,

(CH₂)_nC₃-C₈ cycloalkyl,

C(O)R⁹,

C(O)OR⁹,

C(=NOR⁸)R⁹,

CR⁸(OH)R⁹,

C[=C(R⁸)₂]R⁹,

OR⁹,

SR⁹ or

S(O)_pR⁹;

R^8 is: hydrogen or C_1 - C_6 alkyl; and

R^9 is: hydrogen,

C_1 - C_6 alkyl,

C_3 - C_8 cycloalkyl,

aryl,


heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl.

3. (Original). The compound of Claim 2, wherein Z is optionally substituted phenyl or naphthyl, furanyl, imidazolyl, indolyl, oxazolyl, isoxazolyl, pyridyl, pyrrolyl, thiazolyl, thiophenyl, benzofuranyl, benzothiophenyl, benzoisoxazolyl, quinolinyl, isoquinolinyl or a structural formula selected from following:



wherein T is:


a bond, $-(CH_2)_qO-$, $-O(CH_2)_q-$, $-C(O)(CH_2)_q-$, $-(CH_2)_qC(O)-$, $-(CH_2)_qS-$, $-S(CH_2)_q-$, $S[O]_p$, $-(C_1-C_3 \text{ alkyl})-$, $-(CH_2)_qC(=CH_2)-$, $-C(=CH_2)(CH_2)_q-$, $-(CH_2)_qC(=NOH)-$, $-C(=NOH)(CH_2)_q-$, $-(CH_2)_qC(=NOCH_3)-$, $-C(=NOCH_3)(CH_2)_q-$, $-CH(OH)(CH_2)_q-$, or $-(CH_2)_qCH(OH)-$,

q is: 0, 1, 2 or 3; and


rings b to l are each optionally substituted with one or more groups independently selected from the group consisting of:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_n C_3$ - C_8 cycloalkyl.

4. (Withdrawn) The compound of Claim 2, wherein the compound having a structural formula III,



5. (Currently Amended). The compound of ~~Claim 4~~ Claim 2, wherein the compound ~~having a~~ is represented by structural formula IV,



or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

- O and O,
- CH_2 and O,
- CH_2 and S,
- O and S or
- S and O;

m is: 1 or 2;

R^1 is: C_1 - C_3 alkyl;

R^3 is: hydrogen, halo or C_1 - C_6 alkyl;


R^6 and R^9 are each independently: hydrogen or C_1 - C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O)-S(O) $_2$ -, -C(=CH $_2$)-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, S(O) $_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and (CH $_2$) $_n$ C $_3$ -C $_8$ cycloalkyl.

6. (Currently Amended). The compound of Claim 5, wherein the compound ~~having a~~ is represented by structural formula V,



or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:


T is: a bond, -O- or -C(O)-;

R^1 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and


rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF $_3$, OCF $_3$, methyl, ethyl, isopropyl, N(CH $_3$) $_2$, S(O) $_2$ CH $_3$, methoxy and cyclopropyl.

7. (Original). The compound of Claim 6, wherein the compound is represented by a structural formula VI,




or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8. (Withdrawn) The compound of Claim 2, wherein the compound having a structural formula VII,



Z is:



A₁ and A₂ are respectively: bond and S; bond and O; CH₂ and S; or CH₂ and O;

m is: 1 or 2;

R¹ is: C₁-C₃ alkyl;

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;


T is: bond, -O-, -C(O)-, -S(O)-S(O)₂-, -C(=CH₂)-, -C(=NOH)- or -CH(OH)-; and

rings b, c, k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_n$ - C_3 - C_8 cycloalkyl.

9. (Withdrawn) The compound of Claim 8, wherein R^1 is: methyl, ethyl or cyclopropyl; R^3 is: methyl or ethyl; and rings b, c k and l are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3 , OCF_3 , $N(CH_3)_2$, $S(O)_2CH_3$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

10. (Currently Amended). The compound of ~~Claim 4~~ Claim 2, wherein the compound ~~having a~~ is represented by structural formula VIII,



VIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

- O and O,
- CH_2 and O,
- CH_2 and S,
- O and S or
- S and O;

m is: 1 or 2;

R^1 is: C_1 - C_3 alkyl; and

R^3 is: hydrogen, halo or C_1 - C_6 alkyl;


R^6 and R^9 are each independently: hydrogen or C_1 - C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O)- $S(O)_2$ -, -C(=CH₂)-, -C(=NOH)- or -CH(OH)-; and

ring b is optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_n C_3$ - C_8 cycloalkyl.

11. (Currently Amended). The compound of Claim 10, wherein the compound ~~having a~~ is represented by structural formula IX,




or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

R^1 is C_1 - C_3 alkyl;

R^3 is: hydrogen, halo or C_1 - C_4 alkyl;


ring b is optionally substituted with one or more groups independently selected from the group consisting of: hydrogen, halo, haloalkyl, haloalkyloxy and C_1 - C_6 alkyl.

12. (Currently Amended). The compound of Claim 11, wherein the compound ~~having a~~ is represented by structural formula X,



or a pharmaceutically acceptable salt, solvate or hydrate thereof.


13. (Currently Amended). The compound of Claim 11, wherein the compound ~~having a~~ is represented by structural formula XI,



XI

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

14. (Currently Amended). The compound of ~~Claim 4~~ Claim 2, wherein the compound ~~having a~~ is represented by structural formula XII,



XII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ and A₂ are respectively:

- O and O,
- CH₂ and O,
- CH₂ and S,
- O and S or
- S and O;

m is: 1 or 2;

R¹ is: C₁-C₃ alkyl; and

R³ is: hydrogen, halo or C₁-C₆ alkyl;


R⁴, R⁵, R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

rings k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, S(O)₂R⁹, C₁-C₆ alkyl, C₁-C₆ alkoxy and (CH₂)_nC₃-C₈ cycloalkyl.

15. (Canceled)

16. (Currently Amended). The compound of Claim 2, wherein the compound ~~having a~~ is represented by structural formula XIII,




XIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein m is 1, 2, 3, or 4.

17. (Canceled).

18. (Currently Amended). The compound of ~~Claim 17~~ Claim 16, wherein the compound ~~having a~~ is represented by structural formula XV,



XV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:


T is: a bond, O or C(O);

R² is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, N(CH₃)₂, S(O)₂CH₃, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

19. (Currently Amended). The compound of Claim 2, wherein the compound ~~having a~~ is represented by structural formula XVI,




XVI

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein Y is a branched alkyl or C₃-C₆ cycloalkyl.

20. (Canceled).

21. (Currently Amended). The compound of ~~Claim 20~~ Claim 19, wherein the compound ~~having a~~ structural formula XVIII,



XVIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);


R³ is: methyl or ethyl;

R^{9a} and R^{9b} are each independently hydrogen, methyl or ethyl, wherein at least one of R^{9a} and R^{9b} being methyl or ethyl;

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, S(O)₂CH₃, N(CH₃)₂, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

22. (Canceled).

23. (Currently Amended). The compound of Claim 1, wherein the compound ~~having a~~ is a compound of formula XX,



XX

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

A₂ is: O or S or CH₂;

Q is: -C(O)OR⁶, or R^{6A};

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

Z is: a) aryl;
 b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
 c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
 d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R⁷;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1 - C_6 alkyl,

$(CH_2)_n C_3$ - C_8 cycloalkyl, or

R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R^3 is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C_1 - C_6 alkyl,


C_1 - C_6 alkoxy, or

C_3 - C_8 cycloalkyl;

R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl;

R^6 is: hydrogen, C_1 - C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



R^7 is: hydrogen,
 oxo,
 nitro,
 cyano,
 hydroxyl,
 halo,
 haloalkyl,
 haloalkyloxy,
 aryloxy,
 arylalkyl,
 aminoalkyl,
 C_1-C_6 alkyl,
 C_1-C_6 alkoxy,
 $(CH_2)_n C_3-C_8$ cycloalkyl,
 $C(O)R^9$,
 $C(O)OR^9$,
 $C(=NOR^8)R^9$,
 $CR^8(OH)R^9$,
 $C[=C(R^8)_2]R^9$,
 OR^9 ,
 SR^9 or
 $S(O)_p R^9$;


R^8 is: hydrogen or C_1-C_6 alkyl; and

R⁹ is: hydrogen,
C₁-C₆ alkyl,
C₃-C₈ cycloalkyl,
aryl,
heteroaryl or
heterocyclyl,
wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:
hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,
C₁-C₆ alkyl, C₁-C₆ alkoxy and C₃-C₈ cycloalkyl.

24. (Canceled).

25. (Canceled).

26. (Currently Amended). The compound of ~~Claim 25~~ Claim 23, wherein the compound ~~having a~~ is a compound of structural formula XXII,



or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:


T is: a bond, -O- or -C(O)-;

R¹ is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, S(O)₂CH₃, N(CH₃)₂, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

27. (Currently Amended). The compound of Claim 1, wherein the compound ~~having a~~ is a compound of structural formula XXIII,



or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ and A₂ are respectively:

- O and O,
- CH₂ and O,
- CH₂ and S,
- O and S or
- S and O;

m is: 1, 2, 3 or 4;

R¹ is: C₁-C₃ alkyl; and

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

T is: a bond, -O-, -C(O)-, -S(O)-S(O)₂-, -C(=CH₂)-, -C(=NOH)- or -CH(OH)-; and






rings b and c are each optionally substituted with one or more groups independently selected from:






hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, S(O)₂R⁹, C₁-C₆ alkyl, C₁-C₆ alkoxy and (CH₂)_nC₃-C₈ cycloalkyl.







28. (Canceled).






29. (Currently Amended). A compound of Claim 1 selected from the group consisting of:







No.	Structure	Name
1		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
2		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-acetic acid
3		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
4		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
5		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid






No.	Structure	Name
6		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
7		2-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
8		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-acetic acid
9		3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
10	<div style="text-align: right;">Chiral</div> 	3-{4-[3-(2-Benzoyl-4-cyclopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	Name
11		3-{4-[3-(2-Benzoyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
12		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
13		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
14		3-{4-[3-(2-Benzoyl-4-methoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
15		3-{4-[3-(2-Benzoyl-4-fluoro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	<u>Name</u>
16		3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
17		{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
18		3-(4-{3-[4-Ethyl-2-(hydroxy-phenyl)-methyl]-phenoxy}-butoxy)-2-methyl-phenyl)-propionic acid
19		3-(4-{3-[4-Ethyl-2-(hydroxyimino-phenyl)-methyl]-phenoxy}-butoxy)-2-methyl-phenyl)-propionic acid
20		3-(4-{3-[4-Ethyl-2-(methoxyimino-phenyl)-methyl]-phenoxy}-butoxy)-2-methyl-phenyl)-propionic acid
21		3-{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	<u>Name</u>
22		{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
23		3-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
24		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
25		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
26		3-{4-[3-(2-Cyclopentanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	<u>Name</u>
27		2-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
28		2-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
29		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
30		{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
31	<div style="text-align: right;">Chiral</div> 	3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
32	<div style="text-align: right;">Chiral</div> 	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid






No.	Structure	Name
33		3-{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
34		{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
35		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
36		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-ethyl-phenyl}-propionic acid
37		{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid






No.	Structure	Name
38		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
39		3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
40		3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
41		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)
42		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	Name
43		3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
44		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
45		3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid
46		3-{4-[3-(5-Ethyl-biphenyl-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
47		3-{4-[3-(4-Ethyl-2-oxazol-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
48		3-{4-[3-(4-Ethyl-2-thiazol-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	Name
49	<div style="text-align: right;">Chiral</div> 	3-{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
50	<div style="text-align: right;">Chiral</div> 	{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
51	<div style="text-align: right;">Chiral</div> 	3-{2-Ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic acid
52	<div style="text-align: right;">Chiral</div> 	3-{4-[3-(4-Chloro-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
53	<div style="text-align: right;">Chiral</div> 	3-{2-Methyl-4-[3-(2-trifluoromethyl-phenoxy)-butoxy]-pyridin-2-yl-4-trifluoromethyl-phenoxy}-propionic acid
54	<div style="text-align: right;">Chiral</div> 	3-{2-Ethyl-4-[3-(2-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid







No.	Structure	Name
55		3-{4-[3-(4-Ethyl-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
56		3-{4-[3-(4-Chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
57		3-{4-[3-(4-Ethyl-2-pyridin-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
58		3-{2-Methyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
59		3-{2-Ethyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
60		3-{4-[3-(2-chloro-4-benzodisoxazol-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	<u>Name</u>
61		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
62		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-acetic acid
63		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
64		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
65		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid






No.	Structure	<u>Name</u>
66		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
67		2-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
68		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-acetic acid
69		3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
70	<div style="display: flex; align-items: center;">  <div style="margin-left: 10px;">Chiral</div> </div>	3-{4-[3-(2-Benzoyl-4-cyclopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	Name
71		3-{4-[3-(2-Benzoyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
72		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
73		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
74	<div>Chiral</div> 	3-{4-[3-(2-Benzoyl-4-methoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
75	<div>Chiral</div> 	3-{4-[3-(2-Benzoyl-4-fluoro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	Name
76		Chiral 3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
77		Chiral {4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
78		{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
79		3-(4-{3-[4-Ethyl-2-(hydroxy-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
80		3-(4-{3-[4-Ethyl-2-(hydroxyimino-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid







No.	Structure	<u>Name</u>
81		3-(4-{3-[4-Ethyl-2-(methoxyimino-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
82		3-{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
83		{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
84		3-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
85		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
86		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	Name
87		3-{4-[3-(2-Cyclopentanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
88		2-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
89		2-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
90		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
91		{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
92		3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	<u>Name</u>
93	<div style="text-align: right;">Chiral</div> 	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
94	<div style="text-align: right;">Chiral</div> 	3-{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
95	<div style="text-align: right;">Chiral</div> 	{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
96	<div style="text-align: right;">Chiral</div> 	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
97	<div style="text-align: right;">Chiral</div> 	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-ethyl-phenyl}-propionic acid






No.	Structure	Name
98		{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
99		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
100		3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
101		3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
102		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)






No.	Structure	Name
103		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
104		3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
105		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
106	<div>Chiral</div> 	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid
107		3-{4-[3-(5-Ethyl-biphenyl-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
108	<div>Chiral</div> 	3-{4-[3-(4-Ethyl-2-oxazol-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	<u>Name</u>
109	 <p>Chiral</p>	3-{4-[3-(4-Ethyl-2-thiazol-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
110	 <p>Chiral</p>	3-{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
111	 <p>Chiral</p>	{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
112	 <p>Chiral</p>	3-{2-Ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic acid
113	 <p>Chiral</p>	3-{4-[3-(4-Chloro-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
114	 <p>Chiral</p>	3-{2-Methyl-4-[3-(2-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid

No.	Structure	<u>Name</u>
115		3-{2-Ethyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
116		3-{4-[3-(4-Ethyl-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
117		3-{4-[3-(4-Chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
118		3-{4-[3-(4-Ethyl-2-pyridin-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
119		3-{2-Methyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
120		3-{2-Ethyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid






No.	Structure	Name
121	 <p>Chiral</p>	3-{4-[3-(2-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
122	 <p>Chiral</p>	(R)-{4-[3-(4-ethyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
123	 <p>Chiral</p>	(R)-{4-[3-(2-benzoyl-4-methyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
124	 <p>Chiral</p>	(R)-{4-[3-(2-benzoyl-4-trifluoromethoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
125		{4-[3-(2-benzoyl-4-ethyl-phenoxy)-hexyloxy]-2-methyl-phenylsulfanyl}-acetic acid





No.	Structure	Name
126		3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-hexyloxy]-2-methyl-phenyl}-propionic acid
127	<div style="text-align: right;">Chiral</div> 	(R)-3-{4-[3-(4-ethyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
128	<div style="text-align: right;">Chiral</div> 	(R)-3-(4-{3-[4-ethyl-2-(1-phenyl-vinyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
129	<div style="text-align: right;">Chiral</div> 	(R)-3-(4-{3-[4-ethyl-2-(1-methyl-1-phenyl-ethyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
130	<div style="text-align: right;">Chiral</div> 	(R)-3-{4-[3-(2-benzoyl-4-methyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid





No.	Structure	Name
131		(R)-3-(4-{3-[4-ethyl-2-(1-phenyl-ethyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
132		(R)-3-(4-{3-[4-ethyl-2-(pyridine-2-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
133		3-(2-methyl-4-{3-[2-(thiophene-2-carbonyl)-4-trifluoromethoxy-phenoxy]-butoxy}-phenyl)-propionic acid
134		3-(4-{3-[4-ethyl-2-(thiophene-2-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
135		3-(4-{3-[4-ethyl-2-(naphthalene-1-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid







No.	Structure	<u>Name</u>
136		3-(4-{3-[4-ethyl-2-(1-phenyl-vinyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
137		3-{4-[3-(2-benzoyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
138		3-{4-[3-(2-benzoyl-4-methyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
139		3-{4-[3-(2-benzyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
140		3-{4-[3-(2-benzoyl-4-bromo-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	Name
141		3-{4-[3-(2-benzoyl-4-butyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
142		3-{4-[3-(2-benzoyl-4-propyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
143		3-{4-[4-(2-benzoyl-4-ethyl-phenoxy)-1-methyl-butoxy]-2-methyl-phenyl}-propionic acid
144		3-{4-[4-(2-benzoyl-4-ethyl-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid
145		3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-2-methyl-propoxy]-2-methyl-phenyl}-propionic acid
146		3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	Name
147		3-(4-{3-[4-ethyl-2-(4-fluorobenzoyl)phenoxy]propoxy}-2-methylphenyl)-propionic acid
148		3-(4-{3-[4-ethyl-2-(2-trifluoromethylbenzoyl)phenoxy]propoxy}-2-methylphenyl)-propionic acid
149		3-(4-{3-[4-ethyl-2-(3-trifluoromethylbenzoyl)phenoxy]propoxy}-2-methylphenyl)-propionic acid
150		3-(4-{3-[4-ethyl-2-(thiophene-2-carbonyl)phenoxy]propoxy}-2-methylphenyl)-propionic acid
151		3-{4-[3-(2-benzyl-4-ethylphenoxy)propoxy]-2-methylphenyl}-propionic acid







No.	Structure	<u>Name</u>
152		3-(4-{3-[4-ethyl-2-(naphthalene-1-carbonyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
153		3-(4-{3-[4-ethyl-2-(1-phenyl-vinyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
154		2-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
155		2-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-2-methyl-propoxy]-phenoxy}-2-methyl-propionic acid







No.	Structure	<u>Name</u>
156		2-{4-[3-(2-benzyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
157		2-{4-[3-(2-benzoyl-4-bromo-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
158		2-{4-[3-(2-benzoyl-4-butyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
159	<div style="text-align: right;">Chiral</div> 	(R)- 3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	Name
160	<p style="text-align: right;">Chiral</p> 	(R)-3-{2-methyl-4-[3-(2-phenoxy-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
161	<p style="text-align: right;">Chiral</p> 	(R)-3-{2-methyl-4-[3-(2-phenoxy-4-trifluoromethoxy-phenoxy)-butoxy]-phenyl}-propionic acid
162	<p style="text-align: right;">Chiral</p> 	(R)-3-{2-methyl-4-[3-(4-methyl-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
163	<p style="text-align: right;">Chiral</p> 	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
164		3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid
165	<p style="text-align: right;">Chiral</p> 	(R)-3-{4-[3-(2-benzo[b]thiophen-3-yl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid







No.	Structure	Name
166	<p style="text-align: right;">Chiral</p> 	(R)- 3-{4-[3-(4-chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
167	<p style="text-align: right;">Chiral</p> 	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-2,2-difluoro-propionic acid
168	<p style="text-align: right;">Chiral</p> 	%(R)-3-{3-bromo-4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
169	<p style="text-align: right;">Chiral</p> 	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-3-methyl-phenyl}-propionic acid
170	<p style="text-align: right;">Chiral</p> 	(R)-{3-bromo-4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-acetic acid
171	<p style="text-align: right;">Chiral</p> 	(R)-3-{4-[3-(4-bromo-2-trifluoromethoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid






No.	Structure	<u>Name</u>
172	<p style="text-align: right;">Chiral</p> 	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-3-methyl-phenyl}-acetic acid
173	<p style="text-align: right;">Chiral</p> 	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-acetic acid
174	<p style="text-align: right;">Chiral</p> 	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-trifluoromethyl-phenyl}-propionic acid
175	<p style="text-align: right;">Chiral</p> 	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid
176	<p style="text-align: right;">Chiral</p> 	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid





No.	Structure	<u>Name</u>
177	 <p>Chiral</p>	(R)-3-{2-Chloro-4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
178	 <p>Chiral</p>	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-fluorophenyl}-propionic acid
179	 <p>Chiral</p>	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethylphenyl}-propionic acid
180	 <p>Chiral</p>	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-chlorophenyl}-propionic acid
181	 <p>Chiral</p>	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-fluorophenyl}-propionic acid
182	 <p>Chiral</p>	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid






No.	Structure	<u>Name</u>
183	 <p>Chiral</p>	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenyl}-propionic acid
184	 <p>Chiral Isomer 1</p>	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid
185	 <p>Chiral Isomer 1</p>	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid
186	 <p>Chiral</p>	(R)-{4-[3-(3-Benzoyl-naphthalen-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
187	 <p>Chiral</p>	(R)-3-{4-[3-(3-Benzoyl-naphthalen-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
188	 <p>Chiral</p>	(R)-3-{4-[3-(4-Ethyl-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid



No.	Structure	Name
189		(R)-3-{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
190		(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-propyl-phenyl}-propionic acid
191		(R)-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethyl-phenylsulfanyl}-acetic acid
192		(R)-3-{4-[3-(2-Benzoyl-4,5-dichloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
193		(R)-3-{2-Methyl-4-[3-(2-phenoxy-4-trifluoromethyl-phenoxy)-butylsulfanyl]-phenyl}-propionic acid
194		(R)-3-{2-Ethyl-4-[3-(4-ethyl-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
195	 <p>Chiral</p>	(R)-3-{2-Ethyl-4-[3-(2-phenoxy-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
196	 <p>Chiral</p>	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid
197	 <p>Chiral</p>	(R)-3-{2-Ethyl-4-[1-methyl-3-(2-phenoxy-4-trifluoromethyl-phenoxy)-propoxy]-phenyl}-propionic acid
198	 <p>Chiral</p>	(R)-3-{2-Methyl-4-[1-methyl-3-(2-phenoxy-4-trifluoromethoxy-phenoxy)-propylsulfanyl]-phenyl}-propionic acid
199	 <p>Chiral</p>	(S)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid
200		3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-propoxy]-2-ethyl-phenyl}-propionic acid


No.	Structure	Name
201	 <p>Chiral</p>	(R)-3-{4-[3-(2,4-Diphenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid
202	 <p>Chiral Cis - Isomer 2</p>	2-{4-[4-(4-Chloro-2-phenoxy-phenyl)-3-methyl-butoxy]-2-methyl-phenyl}-cyclopropanecarboxylic acid
203		(R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
204		2-{4-[3-(R,S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-2-methyl-propionic acid (enantiomer pair 1)
205		(R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid

No.	Structure	Name
206		(R, S)-2-Methyl-2-{4-[3-(2-methyl-3-phenyl-7-propyl-benzofuran-6-yloxy)-butoxy]-phenoxy}-propionic acid
207		(R, S)-2-Methyl-2-{4-[3-(4-methyl-3-phenyl-7-propyl-benzofuran-6-yloxy)-butoxy]-phenoxy}-propionic acid
208		(R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
209		(R, S)-3-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	<u>Name</u>
210	 <p style="text-align: right;">Chiral</p>	3-{R-4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
211		3-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid isomer 2
212		(R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
213		(R, S)-3-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
214		(R, S)-2-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid

No.	Structure	Name
215		(R, S)-3-{4-[3-(2-ethoxyphenyl)-2-methyl-phenyl]-propoxy}-4-ethylphenyl benzenesulfonate
216		3-{4-[3-(2-benzoyl-4-trifluoromethoxyphenyl)-2-methyl-phenyl]-propoxy}-4-ethylphenyl benzoate

30. (Original). The compound of Claim 29, wherein the compound is



or a pharmaceutically acceptable salt, solvate or hydrate thereof.

31. (Currently Amended). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of ~~Claims 1-30~~ Claim 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof.

32. (Currently Amended). A pharmaceutical composition comprising:

(1) a compound of ~~Claims 1-30~~ Claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof;

(2) a second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α -glucosidase inhibitors, insulin secretagogues, insulin, antihyperlipidemic agents, plasma HDL-raising

agents, HMG-CoA reductase inhibitors, statins, acyl CoA:cholesterol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin; and

(3) optionally a pharmaceutically acceptable carrier.

33. (Canceled).

34. (Canceled).

35. (Canceled).

36. (Canceled).

37. (Canceled).

38. (Canceled).

39. (Canceled).

40. (Canceled).

41. (Canceled).

42. (Canceled).

43. (Currently Amended). A method for lowering blood-glucose in a mammal in need thereof comprising the step of administering an effective amount of a compound of ~~Claims 1-30~~ Claim 1.

44. (Currently Amended). A method of treating or preventing disease or condition in a mammal in need thereof selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of a compound of ~~Claims 1-30~~ Claim 1.

45. (Currently Amended). A method of treating or preventing diabetes mellitus in a mammal in need thereof comprising the step of administering to a mammal a therapeutically effective amount of a compound of ~~Claims 1-30~~ Claim 1.

46. (Currently Amended). A method of treating or preventing cardiovascular disease in a mammal in need thereof comprising the step of administering to a

mammal a therapeutically effective amount of a compound of ~~Claims 1-30~~ Claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

47. (Canceled).

48. (Currently Amended). A method of treating or preventing disease or condition in a mammal in need thereof selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of a compound of ~~Claims 1-30~~ Claim 1 and an effective amount of second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α -glucosidase inhibitors, insulin secretagogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors, statins, acyl CoA:cholesterol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin.

49. (Canceled)